FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2801624843> ?p ?o ?g. }

• W2801624843 abstract "Objective: To define the frequency, duration and severity of intractable nausea, vomiting or hiccups (INVH) in NMOSD Background: INVH are symptoms of inflammation targeted to AQP4-expressing astrocytes in the AP. Published data relating to frequency, duration, and severity of INVH are lacking. Design/Methods: Of 541 patients with AQP4-IgG-positive NMOSD in Mayo Clinic’s database, 200 reported INVH at some point. To date, 52 patients with a history of INVH have been surveyed by telephone. Results: INVH occurred in the first attack in 26 (50%) patients. All 3 symptoms (NVH) were present in 31 patients, 2 symptoms in 16 and only a single symptom in 5 (N [1], H [4]). Nausea was acute in onset in 3248 patients (60%). The median duration of nausea was 19 days (range 3–90). Forty-four experienced vomiting with a median vomitus frequency of 6/day (range 2–20). Patients usually reported vomiting rapidly after eating liquid or solid. Sixteen were awakened by vomiting. Weight loss was reported in 16 patients (median 16lbs, range 3–70). Hiccups occurred in 35 and lasted all day (non-stop) for median of 30 days (range 3–90) in 9. Fifteen patients were awakened from sleep by hiccups. INVH led to hospitalization and IV rehydration in 32 patients. Twenty one (40%) patients presented to gastroenterologists and in 12 diagnosis assigned as gastritis (2), cyclic-vomiting syndrome (3), gastroparesis (3), cholecytitis (1) and Crohn’s disease (1), food poisoning (1), pancreatitis (1). All 21 patients receiving intravenous methylprednisolone or plasmapharesis showed resolution of NVH. INVH commonly preceded other symptoms of NMOSD exacerbation (optic neuritis in18, 34 %; transverse myelitis in 26, 50%, brainstem syndromes in 2, 4%) within median of 2 weeks (range 0–4) after INVH onset Conclusions: These data characterize the “area postrema” attack phenotype and will assist in development of diagnostic criteria and severity indices for such attacks Study Supported by: Mayo Clinic Foundation Disclosure: Dr. Shosha has nothing to disclose. Dr. Majed has nothing to disclose. Dr. Weinshenker has received personal compensation for activities with Novartis, Mitsubishi Pharmaceuticals, Medimmune and Alexion Pharmaceuticals. Dr. Weinshenker has received (royalty or license fee or contractual rights) payments from RSR Ltd., Oxford University and MVZ Labor PD and Mayo Foundation. Dr. Flanagan has nothing to disclose. Dr. Huebert has nothing to disclose. Dr. Sagen has nothing to disclose. Dr. Levy has received personal compensation from Alexion, Guidepoint Global, Genzyme and Acorda. Dr. Greenberg has received personal compensation for activities with Novartis Boston Pharmaceuticals, and MSAA. Dr. Greenberg has received personal compensation in an editorial capacity for JAMA Neurology. Dr. Greenberg has received research support from Medimmune, Acorda, and Chugai. Dr. Pittock9s institution has received compensation for Dr. Pittock9s activities with Alexion Pharmaceuticals, Medimmune and Chugai Pharma USA. Dr. Pittock and Dr. Pittock9s institution stand to receive patent payments that relate to patents for functional AQP4/NMO-IgG assays and NMO-IgG as a cancer marker. Dr. Pittock has received research support from NIH, Alexion Pharmaceuticals and Medimmune related to autoimmune NMO/AQP4 channelopathy." @default.
• W2801624843 created "2018-05-17" @default.
• W2801624843 creator A5000669492 @default.
• W2801624843 creator A5012566800 @default.
• W2801624843 creator A5027362230 @default.
• W2801624843 creator A5032891503 @default.
• W2801624843 creator A5040310040 @default.
• W2801624843 creator A5069405668 @default.
• W2801624843 creator A5080779706 @default.
• W2801624843 creator A5088136783 @default.
• W2801624843 creator A5088963233 @default.
• W2801624843 date "2017-04-18" @default.
• W2801624843 modified "2023-09-23" @default.
• W2801624843 title "Defining Area Postrema (AP) Attacks in Autoimmune AQP4 Channelopathies/Neuromyelitis Optica Spectrum Disorders (NMOSD) (P6.386)" @default.
• W2801624843 hasPublicationYear "2017" @default.
• W2801624843 type Work @default.
• W2801624843 sameAs 2801624843 @default.
• W2801624843 citedByCount "0" @default.
• W2801624843 crossrefType "journal-article" @default.
• W2801624843 hasAuthorship W2801624843A5000669492 @default.
• W2801624843 hasAuthorship W2801624843A5012566800 @default.
• W2801624843 hasAuthorship W2801624843A5027362230 @default.
• W2801624843 hasAuthorship W2801624843A5032891503 @default.
• W2801624843 hasAuthorship W2801624843A5040310040 @default.
• W2801624843 hasAuthorship W2801624843A5069405668 @default.
• W2801624843 hasAuthorship W2801624843A5080779706 @default.
• W2801624843 hasAuthorship W2801624843A5088136783 @default.
• W2801624843 hasAuthorship W2801624843A5088963233 @default.
• W2801624843 hasConcept C118552586 @default.
• W2801624843 hasConcept C126322002 @default.
• W2801624843 hasConcept C187212893 @default.
• W2801624843 hasConcept C2778769438 @default.
• W2801624843 hasConcept C2779422922 @default.
• W2801624843 hasConcept C2779761075 @default.
• W2801624843 hasConcept C2780580376 @default.
• W2801624843 hasConcept C2780640218 @default.
• W2801624843 hasConcept C2780852908 @default.
• W2801624843 hasConcept C2781137167 @default.
• W2801624843 hasConcept C3020479747 @default.
• W2801624843 hasConcept C42219234 @default.
• W2801624843 hasConcept C71924100 @default.
• W2801624843 hasConcept C90924648 @default.
• W2801624843 hasConceptScore W2801624843C118552586 @default.
• W2801624843 hasConceptScore W2801624843C126322002 @default.
• W2801624843 hasConceptScore W2801624843C187212893 @default.
• W2801624843 hasConceptScore W2801624843C2778769438 @default.
• W2801624843 hasConceptScore W2801624843C2779422922 @default.
• W2801624843 hasConceptScore W2801624843C2779761075 @default.
• W2801624843 hasConceptScore W2801624843C2780580376 @default.
• W2801624843 hasConceptScore W2801624843C2780640218 @default.
• W2801624843 hasConceptScore W2801624843C2780852908 @default.
• W2801624843 hasConceptScore W2801624843C2781137167 @default.
• W2801624843 hasConceptScore W2801624843C3020479747 @default.
• W2801624843 hasConceptScore W2801624843C42219234 @default.
• W2801624843 hasConceptScore W2801624843C71924100 @default.
• W2801624843 hasConceptScore W2801624843C90924648 @default.
• W2801624843 hasOpenAccess W2801624843 @default.
• W2801624843 hasRelatedWork W1503880426 @default.
• W2801624843 hasRelatedWork W1531883432 @default.
• W2801624843 hasRelatedWork W1569853514 @default.
• W2801624843 hasRelatedWork W1577110513 @default.
• W2801624843 hasRelatedWork W1586096696 @default.
• W2801624843 hasRelatedWork W1771833678 @default.
• W2801624843 hasRelatedWork W1972929666 @default.
• W2801624843 hasRelatedWork W2112295192 @default.
• W2801624843 hasRelatedWork W2323391828 @default.
• W2801624843 hasRelatedWork W2326776893 @default.
• W2801624843 hasRelatedWork W2336774134 @default.
• W2801624843 hasRelatedWork W2337454421 @default.
• W2801624843 hasRelatedWork W2562813342 @default.
• W2801624843 hasRelatedWork W2565307653 @default.
• W2801624843 hasRelatedWork W2584409149 @default.
• W2801624843 hasRelatedWork W2809349490 @default.
• W2801624843 hasRelatedWork W2897299659 @default.
• W2801624843 hasRelatedWork W3082561848 @default.
• W2801624843 hasRelatedWork W3110176332 @default.
• W2801624843 hasRelatedWork W3138490260 @default.
• W2801624843 hasVolume "88" @default.
• W2801624843 isParatext "false" @default.
• W2801624843 isRetracted "false" @default.
• W2801624843 magId "2801624843" @default.
• W2801624843 workType "article" @default.